Secondary mutations in BRCA1 and BRCA2 that re-establish the reading frame may restore HRR proficiency and render cancer cells resistant to agents that target DNA damage.19 In this study, exome sequencing showed no secondary BRCA1/2 mutations in either primary or acquired resistance. The gene discussed is BRCA2; the disease is cancer.